| Autor: |
Sekeres, Mikkael A., Schuster, Michael, Joris, Magalie, Krauter, Jürgen, Maertens, Johan, Breems, Dimitri, Gyan, Emmanuel, Kovacsovics, Tibor, Verma, Amit, Vyas, Paresh, Wang, Eunice S., Ching, Keith, O'Brien, Thomas, Gallo Stampino, Corrado, Ma, Weidong Wendy, Kudla, Arthur, Chan, Geoffrey, Zeidan, Amer M. |
| Zdroj: |
Annals of Hematology; Aug2022, Vol. 101 Issue 8, p1689-1701, 13p |
| Abstrakt: |
This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. Of 72 patients enrolled, 12 were in a lead-in safety cohort (LIC) and 60 were in the AML and MDS (including CMML) expansion cohorts. In the LIC, the safety profile of glasdegib + azacitidine was determined to be consistent with those of glasdegib or azacitidine alone, with no evidence of drug–drug interaction. In the expansion cohort, the most frequently (≥ 10%) reported non-hematologic Grade ≥ 3 treatment-emergent adverse events were decreased appetite, electrocardiogram QT prolongation, and hypertension in the AML cohort and sepsis, diarrhea, hypotension, pneumonia, and hyperglycemia in the MDS cohort. Overall response rates in the AML and MDS cohorts were 30.0% and 33.3%, respectively; 47.4% and 46.7% of patients who were transfusion dependent at baseline achieved independence. Median overall survival (95% confidence interval) was 9.2 (6.2–14.0) months and 15.8 (9.3–21.9) months, respectively, and response was associated with molecular mutation clearance. Glasdegib + azacitidine in patients with newly diagnosed AML or MDS demonstrated an acceptable safety profile and preliminary evidence of clinical benefits. Trial registration: ClinicalTrials.gov NCT02367456. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink